When people study cancer, the term “personalized medicine” is used a lot. For years, it sounded like a way to go, not a place to end up. Researchers were working toward something that would never really mean anything until a few more tests were done. Then Merck and Moderna made their Phase 3 data on intismeran autogene public, and that phrase began to mean something.
The study, which was called INTerpath-001, included 1,137 people with high-risk, fully removed stage IIB to IV melanoma. These people have already had surgery to get rid of the tumor. It’s over with the cancer, but only for now. It is well known that melanoma often comes back within two years, and it often does so in places that are very different from where it started. Can we do better than what we have now? That was the quiet but important question that the trial asked.
It looks like yes. When intismeran and Merck’s KEYTRUDA were used together, they met their main goal of recurrence-free survival and a key secondary goal that checked to see if the cancer had spread to other parts of the body. It’s not as important as that second number might seem. Most melanoma recurrences are not in the same area. They have spread. Stopping that spread is the only thing that can really change what happens.
The strange and interesting thing about the vaccine is how it’s made. The exact set of mutations found in each patient’s tumor determines the dose that works best for them. After looking at that mutational “fingerprint,” scientists create an mRNA sequence that codes for up to 34 neoantigens that are specific to that cancer. After being injected, those sequences are read by the body, shown to the immune system, and ideally T-cells are made that know what to attack. It’s not what most people think of when they think of a cancer vaccine. There is no set formula in a vial. It was made to help one person with their illness.
The Phase 2b data shown earlier at the 2026 ASCO Annual Meeting already showed that KEYTRUDA alone cut the risk of recurrence or death by 49%. Over the course of five years, that number was enough to keep the scientific community’s attention on this program. The readout for Phase 3 did not let us down. It’s the first time that an mRNA-based cancer treatment has shown results that are statistically significant and clinically meaningful in a large late-stage trial. It’s also the first time that any regimen has done better than KEYTRUDA alone as an extra treatment for melanoma that has been surgically removed. To give you an idea, KEYTRUDA is already thought of as the standard of care. It’s not a small thing to beat it.
When the news came out, Moderna’s stock went up 101%, which was the biggest one-day gain in the company’s history. This kind of market reaction can change the meaning of a story by focusing on money instead of patients. But it’s important to think about what that number really means: investors were beginning to doubt Moderna’s ability to deliver after COVID. The company’s infrastructure was built with the COVID vaccine. The purpose of this trial is to see if that infrastructure can actually do something that it was always supposed to be able to do.
The road ahead is still very long. Overall survival, which is the most important endpoint and takes the longest to observe, will still be tracked by the trial. Submissions to the government haven’t been made yet. Making an mRNA therapy that is specific to each patient, on a large scale, and in time for clinical use is not an easy task in and of itself. It’s possible that process will become the bottleneck that no one saw coming.
But now something is different. It’s no longer a pipe dream to think that you could read a tumor’s mutational code, use that information to build a targeted immune response, and then see that in a Phase 3 primary endpoint. It took place. Oncologists need to change the way they talk about that, even if it takes years for all the effects to sink in.
Every year, melanoma kills about 8,500 Americans. Globally, it’s going up. Most of the time, people who lose don’t lose because the surgery didn’t work, but because something came back. That’s exactly what the Moderna cancer vaccine is meant to do if it makes it through regulatory review and wider use. Not everyone will be saved. But for a disease where “watch and wait” has always felt like a risk, having another real choice is important.
